Chronic obstructive pulmonary disease J44.99
Synonym(s)
Definition
This section has been translated automatically.
Disease that can be prevented and treated, which is characterized as a "chronic, not fully reversible and typically progressive airway obstruction". The pulmoanel component is characterized by an obstruction of airway flow that is not fully reversible. It is associated with an abnormal inflammatory response caused by particles and gases, which in Europe is primarily caused by cigarette smoke.
Chronic bronchitis is assumed to be present (WHO) if a patient has had coughing + expectoration (=productive cough) for at least 3 consecutive months per year in two consecutive years.
Occurrence/Epidemiology
This section has been translated automatically.
m:>w; prevalence for Central Europe: about 13% of the population > 40 years. Preferably male smokers > 40 years with a long smoking history are affected. The prevalence is increasing in the industrialised countries. In the mortality statistics, COPD ranks 3rd worldwide (after stroke and CHD). Experts estimate the total economic costs caused by the disease at almost ten billion euros annually.
You might also be interested in
Etiopathogenesis
This section has been translated automatically.
Multifactorial.
Inhalation smoking is the most common cause of COPD with almost 90% of cases. Smoking favours respiratory tract infections via mucous membrane irritation and paralysis of the ciliary transport. About 20% of inhalation smokers develop COPD.
Various environmental factors such as SO2, nitrogen oxides, fine dust pollution, etc.
For miners in the coal mining industry, compensation is paid for chronic obstructive bronchitis or emphysema (miner's bronchitis) that occurred after 31.12.1992 after the occupational disease BK-No. 4111. A prerequisite is proof of exposure to a cumulative dose of usually 100 fine dust years (mg/m3) x years.
Further recurrent viral and/or bacterial respiratory tract infections (lead to an increase in COPD (AECOPD) and accelerate the progression of the disease.
Endogenous factors such as:
- lack of or low mucociliary clearance, so-called dyskinetic cilia syndrome (Cartagener syndrome - rare)
- Immunodeficiencies such as IgA and IgG deficiency, cellular defense weaknesses.
- Alpha1-antitrypsin deficiency (Note: all patients with COPD <50 years of age should be tested for alpha1-antitrypsin deficiency.
Chronic bronchitis can be symptomatic of various cardiac and pulmonary diseases such as silicosis, left heart failure, tuberculosis, bronchiectasis.
Clinic
This section has been translated automatically.
Main symptoms: AHA symptoms: shortness of breath, coughing (coughing frequently occurring in the morning - smoker's cough), sputum. Purulent secretion with bacterial superinfection.
In "simple" chronic bronchitis, the general condition is generally good and hardly affected by respiratory distress. With progression of chronic bronchitis, increasing shortness of breath, possibly morning headaches. Difficulty in breathing can lead to weight loss and a considerable reduction in performance.
During physical exertion tachypnea and shortness of breath.
Auscultatory: mostly dry, with larger secretion quantities also damp RGs, with obstruction extended expiration with gulling and humming.
Imaging
This section has been translated automatically.
X-ray or CT examination of the thoracic organs
Laboratory
This section has been translated automatically.
Nonspecific, inflammation parameters such as BSG/CRP increased, IgE, ECP for DD reasons, blood count, hematocrit, blood gas analysis.
In case of purulent sputum bacteriological sputum examination with antibiogram
Exclusion of immunodeficiency diseases (immunoglobulins quantitiav), Alpha1-antitrypsin deficiency (especially Pat. <45 years and/or COPD in the family).
Differential diagnosis
This section has been translated automatically.
bronchial carcinoma, pulmonary tuberculosis, bronchiectasis, bronchial asthma.
Complication(s)(associated diseases
This section has been translated automatically.
AECOPD (Acuteexacerbation of COPD): Acute increase in respiratory distress, coughing and/or (purulent, yellow-greenish) sputum beyond the normal level of daily fluctuations (>24 hours), in severe cases up to an acute asthma attack. Increase during the cold season.
AECOPD, severe: tachypnea, central cyanosis, use of the respiratory muscles, peripheral edema, clouding of consciousness to coma
Late complications: With further progression increasing signs of respiratory global insufficiency, with cor pulmonary and right heart failure, signs of chronic hypoxemia (cyanosis, drum beating finger, watch glass nails); increased risk of bronchial carcinoma.
Comorbidities: increased susceptibility to infections (Caution: Any incipient respiratory infection must be treated immediately with antibiotics), emphysema, bronchiectasis. About 50% of the exacerbation of COPD is caused by infectious agents, mainly respiratory viruses. The most common bacterial pathogens are H. influenza, S. peumoniae and M. catarrhalis. More rarely are Enteobactericaeae and P. aeruginosa.
General therapy
This section has been translated automatically.
The two most important pharmacotherapeutic principles for the treatment of obstructive respiratory diseases are bronchodilatation and anti-inflammation. Accordingly, bronchodilatory and anti-inflammatory substances are used, often in combination. Bronchodilators are equally important in both bronchial asthma and COPD. Since the pathological process in obstructive respiratory diseases takes place primarily in the bronchi or bronchioles, many therapeutic measures are applied topically (by inhalation). Special inhalation systems are used for this purpose.
Basic therapy
- Smoking cessation, avoidance of other noxious substances (e.g. in the workplace)
- Rehabilitation of the paranasal sinuses
- Active vaccination against influenza or specific immunotherapies
- Patient training, physical training measures
- Inhalations and/or tapping massages to facilitate expectoration, respiratory physiological therapy measures.
Internal therapy
This section has been translated automatically.
Medication-based antiobstructive therapy:
- Inhalable, fast/short-acting = Reliever (SABA=short -acting beta2-agonist); duration of action 4-6 hours. Application on demand. (Fenoterol, Reproterol, Salbutamol, Terbutalin)
- Inhalable, long-acting = controller (LABA= long-acting beta2-agonist); duration of action 12 hours(formoterol - e.g. Foradil®-, Salmeterol)
Inhalable sympatholytics (=anticholinergics: have significantly fewer side effects)
- Short-acting: e.g. ipratropium bromide, possibly as a combination preparation ipratropium bromide + fenoterol (e.g. Berodual®)
- Long acting (>24h): e.g. tiotropium bromide (Spiriva®)
Inhalable glucocorticoids (ICS)
Phosphodiesterase 4 inhibitors: e.g. Roflumilast (Daxas® 500ug/Tbl.)
Expectorants (see naturopathy below) for viscous mucus that can only be coughed up with difficulty.
Other therapies
- Long-term oxygen therapy (if necessary, non-invasive home treatment
Naturopathy
This section has been translated automatically.
Chronic obstructive bronchitis, nonproductive cough
Medicinal drugs have proven effective in clinical practice when antitussive and bronchodilator therapy is necessary.
Highly effective antitussives include the pure alkaloids codeine and noscapine, derived from opium. They should only be used for short periods.
The following medicinal substances are indicated for non-productive cough:
- Dry, spasmodic cough:Hedera folium(= ivy leaves); example: Prospan 20-20-20 drops
- Acute coughing fits with early mucus production:Primulaeradix/Thymi herba= primrose root/thyme herb: Example: Bronchipret TP 1-1-1 film-coated tablets)
- Persistent dry cough with minimal mucus production:Plantaginis lanceolatae herba= ribwort plantain (Broncho Sern Syrup 1-1-1 tablets)
- Spasmodic coughing fits with little mucus production: Sundew (Makatussin Drops Drosera 20-20-20 drops)
The following medicinal substances are indicated for productive coughs:
- Spasmodic cough with mucus accumulation: Hedera folium(ivy leaves), Thymi herba(thyme herb); Example: Bronchipret 40-40-40 drops
- Acute coughing fits with heavy mucus production:primrose root/thyme/ribwort plantain (Example: Bronchicum Elixir S, 1-1-1-1 teaspoons)
- Persistent cough with thick mucus production: thyme herb (Aspecton 20-20-20-20 drops)
- Persistent cough with thick mucus and fever: nasturtium, sea horseradish root (Angocin® Anti-Infekt 4-4-4 tablets)
Essential oils are contraindicated.
Tables
This section has been translated automatically.
| Patient group | Characteristics | Spirometry | Exacerbations/year | MRC | CAT |
|---|---|---|---|---|---|
| A | Low risk little symptomatic. | GOLD 1-2 | 1/<1 | 0-1 | >10 |
| B | Low risk more symptomatic. | GOLD 1-2 | 1/<1 | 2/>2 | 10/>10 |
| C | High risk little symptomatic. | GOLD 3-4 | 2/>2 | 0-1 | <10 |
| D | High risk more symptomatic. | GOLD 3-4 | 2/>2 | 2/>2 | 10/>10 |
Incoming links (22)
Beta2 sympathomimetics; Bronchial asthma and comorbidities; Bronchiectasis; Budesonide; Chronic obstructive pulmonary disease; Cineol; Copd; Formoterol; Inhaled glucocorticosteroids; Mepolizumab; ... Show allOutgoing links (25)
Alpha1-antitrypsin deficiency; Beta2 sympathomimetics; Blood gas analysis; Cineol; Drosera herba; Ecp; Fenoterol; Formoterol; Hederae folium; Hematocrit; ... Show allDisclaimer
Please ask your physician for a reliable diagnosis. This website is only meant as a reference.